306296-47-9

Usage

Uses

Used in Pharmaceutical Industry:
(4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-piperazin-1-yl]-4-methyl-1-piperidyl]methanone is used as a pharmaceutical compound for its potential therapeutic effects. The presence of multiple functional groups and its complex structure allows it to interact with various biological targets, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-piperazin-1-yl]-4-methyl-1-piperidyl]methanone serves as a subject for studying the synthesis and properties of complex organic molecules. Its unique structure can provide insights into the development of new synthetic methods and the exploration of novel chemical reactions.
Used in Material Science:
(4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-piperazin-1-yl]-4-methyl-1-piperidyl]methanone can be utilized in material science for the development of new materials with specific properties. Its complex structure and functional groups may contribute to the creation of materials with unique characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1

Upstream product

• 157335-93-8 4,6-dimethylpyrimidine-5-carboxylic acid 
• 696601-20-4 (S)-1-[(R)-2-Methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-2-methyl-4-(4-methyl-piperidin-4-yl)-piperazine 
• 745810-23-5 4-Cyano-4-{(S)-4-[(R)-2-methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-piperidine-1-carboxylic acid tert-butyl ester 
• 306298-26-0 4-{(S)-4-[(R)-2-Methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-4-methyl-piperidine-1-carboxylic acid tert-butyl ester 
• 306298-24-8 (S)-4-[(R)-2-Methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 612494-07-2 (S)-1-[(R)-2-Methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-2-methyl-piperazine 
• 612493-99-9 Methanesulfonic acid (S)-2-methoxy-1-(4-trifluoromethyl-phenyl)-ethyl ester 
• 612493-93-3 (S)-2-methoxy-1-(4-trifluoromethylphenyl)ethanol 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 26771-69-7 2-methoxy-1-(4-(trifluoromethyl)phenyl)ethan-1-one 

Relevant academic research and scientific papers

Forward- and reverse-synthesis of piperazinopiperidine amide analogs: A general access to structurally diverse 4-piperazinopiperidine-based CCR5 antagonists

Piperazinopiperidine amide analogs are among the most promising CCR5 antagonists. As an effective extension of a previously-reported methodology to synthesize such compounds, forward- and reverse-syntheses were successfully developed in which the convergent synthesis of the piperazinopiperidine nucleus, with a building block of 4-substituent-4-aminopiperidine, served as a common key step. The two-way approach affords a comprehensive access to the piperazinopiperidine templated library with variation on the pharmacophore sites. Thus, a SAR study of our synthesized piperazinopiperidine-based CCR5 antagonists was conducted with respect to the structure and configuration of the substituent on the piperazine ring. The S-configuration of the benzylic-substituent is vital for the CCR5 binding, and the bulky or aryl substituent on the 2-position in the piperazine ring is detrimental to the activity. By using the forward-synthesis approach, the best compound in the chiral piperazine-based CCR5 antagonist series, Sch-D (Vicriviroc), was conveniently synthesized in an excellent yield. The Royal Society of Chemistry.

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl) carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)-phenyl}ethyl-3(S) -methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Sel

The nature and the size of the benzylic substituent are shown to be the key to controlling receptor selectivity (CCR5 vs M1, M2) and potency in the title compounds. Optimization of the lead benzylic methyl compound 3 led to the methoxymethyl analogue 30,

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter